THEON Acquires Infrared Specialist HGH for €300M

THEON International Plc is set to significantly bolster its defense technology portfolio with an exclusive agreement to acquire SAS Stéropès, the parent entity of SAS HGH Systèmes Infrarouges (HGH). The proposed transaction, valued at an enterprise worth of approximately €300 million (around $336 million USD), marks a strategic move to integrate advanced electro-optical and infrared (EO/IR) capabilities into THEON's offerings.

This acquisition positions THEON to enhance its competitive edge in critical defense sectors, particularly in combating unmanned aerial systems and improving target detection technologies. HGH, a French firm established in 1982, has cultivated deep expertise in designing, developing, and manufacturing sophisticated EO/IR systems for both military and civilian applications. The company's proprietary software and artificial intelligence solutions are notably not subject to US ITAR export controls, a significant advantage for expanding international defense partnerships.

The financial profile of HGH underscores the strategic appeal of this deal. The company generates roughly €40 million in annual revenue and boasts an impressive EBITDA margin exceeding 40%. Furthermore, HGH has demonstrated robust growth, achieving an average annual expansion rate of nearly 30% since 2023. This strong performance trajectory suggests a company well-positioned for continued success within the dynamic defense technology market.

Carlyle, through its Carlyle Europe Technology Partners fund, has been instrumental in HGH's recent development. The private equity firm acquired a majority stake in HGH in 2018 and has since guided the company through a strategic repositioning, focusing on high-growth defense applications. This partnership has evidently fostered innovation and market penetration for HGH, preparing it for its next phase of growth under THEON's ownership.

The integration of HGH's specialized technologies is expected to create substantial synergies for THEON. By incorporating HGH's advanced EO/IR systems, THEON aims to offer more comprehensive solutions for military platforms, addressing evolving threats and operational requirements. The focus on R&D, employing over 130 personnel, highlights HGH's commitment to cutting-edge innovation, a key driver in the defense technology sector where technological superiority is paramount.

The broader defense technology market is experiencing sustained investment, driven by geopolitical shifts and the increasing sophistication of military hardware. Companies specializing in advanced sensing, AI-driven analytics, and counter-drone solutions are seeing heightened demand. HGH's niche in non-ITAR compliant EO/IR technology further enhances its global market potential, allowing for broader accessibility and collaboration with international defense entities.

The transaction is anticipated to conclude by the fourth quarter of 2026, pending the satisfaction of standard closing conditions, including necessary regulatory approvals. This acquisition represents a significant step for THEON in consolidating its position as a key player in the advanced defense systems arena.